Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Felix Gerhard Maria Dietlein, M.D., Ph.D.

Concepts

This page shows the publications Felix Dietlein has written about Humans.
Connection Strength

0.124
  1. An 89Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients. J Nucl Med. 2022 Apr; 63(4):573-583.
    View in: PubMed
    Score: 0.011
  2. [18F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer. Mol Imaging Biol. 2021 04; 23(2):277-286.
    View in: PubMed
    Score: 0.010
  3. Identification of cancer driver genes based on nucleotide context. Nat Genet. 2020 02; 52(2):208-218.
    View in: PubMed
    Score: 0.010
  4. Intraindividual Comparison of 18F-PSMA-1007 with Renally Excreted PSMA Ligands for PSMA PET Imaging in Patients with Relapsed Prostate Cancer. J Nucl Med. 2020 05; 61(5):729-734.
    View in: PubMed
    Score: 0.009
  5. An 18F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with 18F-JK-PSMA-7 During the First Year of Application. J Nucl Med. 2020 02; 61(2):202-209.
    View in: PubMed
    Score: 0.009
  6. PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. J Nucl Med. 2017 06; 58(6):947-952.
    View in: PubMed
    Score: 0.008
  7. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer. Cell. 2015 Jul 02; 162(1):146-59.
    View in: PubMed
    Score: 0.007
  8. Molecular pathways: exploiting tumor-specific molecular defects in DNA repair pathways for precision cancer therapy. Clin Cancer Res. 2014 Dec 01; 20(23):5882-7.
    View in: PubMed
    Score: 0.007
  9. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet. 2014 Aug; 30(8):326-39.
    View in: PubMed
    Score: 0.006
  10. A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discov. 2014 May; 4(5):592-605.
    View in: PubMed
    Score: 0.006
  11. Inferring primary tumor sites from mutation spectra: a meta-analysis of histology-specific aberrations in cancer-derived cell lines. Hum Mol Genet. 2014 Mar 15; 23(6):1527-37.
    View in: PubMed
    Score: 0.006
  12. Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology. Nat Cancer. 2021 Oct; 2(10):1102-1112.
    View in: PubMed
    Score: 0.003
  13. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer. Mol Imaging Biol. 2022 02; 24(1):115-125.
    View in: PubMed
    Score: 0.003
  14. Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell Survival. Cancer Res. 2021 08 01; 81(15):3971-3984.
    View in: PubMed
    Score: 0.003
  15. Integrated molecular drivers coordinate biological and clinical states in melanoma. Nat Genet. 2020 12; 52(12):1373-1383.
    View in: PubMed
    Score: 0.003
  16. Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas. Ann Oncol. 2020 08; 31(8):1011-1020.
    View in: PubMed
    Score: 0.002
  17. Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC. Cell Rep. 2020 04 28; 31(4):107568.
    View in: PubMed
    Score: 0.002
  18. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019 12; 25(12):1916-1927.
    View in: PubMed
    Score: 0.002
  19. Combined Early and Late [68Ga]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels. Mol Imaging Biol. 2019 06; 21(3):558-566.
    View in: PubMed
    Score: 0.002
  20. Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. Oncogene. 2018 10; 37(42):5682-5693.
    View in: PubMed
    Score: 0.002
  21. LIN28B enhanced tumorigenesis in an autochthonous KRASG12V-driven lung carcinoma mouse model. Oncogene. 2018 05; 37(20):2746-2756.
    View in: PubMed
    Score: 0.002
  22. Nuklearmedizin. 2018 02; 57(1):1-3.
    View in: PubMed
    Score: 0.002
  23. Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. Cell Rep. 2017 Sep 19; 20(12):2833-2845.
    View in: PubMed
    Score: 0.002
  24. Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer. Oncotarget. 2015 Nov 17; 6(36):38458-68.
    View in: PubMed
    Score: 0.002
  25. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imaging Biol. 2015 Aug; 17(4):575-84.
    View in: PubMed
    Score: 0.002
  26. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discov. 2014 Feb; 4(2):246-57.
    View in: PubMed
    Score: 0.002
  27. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci U S A. 2012 Oct 16; 109(42):17034-9.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.